Sustained response to erythropoietin for anemia in NK-cell large granular lymphocytosis: A brief case report.
Date
2022-01
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Attention Stats
Abstract
Large granular lymphocytic leukemia (LGL) is a rare lymphoproliferative disorder that involves the T-cell lineage in around 85% of cases and NK-cell lineage in 15%. Most patients require treatment at some point of their disease trajectory to address clinical symptomatology largely pertaining to cytopenia. While immunosuppression represents the backbone of LGL therapy, there is no consensus on the best next line following failure of immunosuppression. Here we present a case of LGL-associated cytopenia in a 73-year-old male refractory to immunosuppression, treated with adjunct erythropoietin alpha (EPO) with a marked response. Our case suggests that EPO therapy may provide therapeutic benefit in refractory LGL cases when used in conjunction with immunosuppressive therapy.
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Kwaramba, Tendai, Brian Lewis, Bruce Burks, Bernardo Ruiz, Swaminathan P Iyer and Firas Safa (2022). Sustained response to erythropoietin for anemia in NK-cell large granular lymphocytosis: A brief case report. Leukemia research reports, 17. p. 100292. 10.1016/j.lrr.2022.100292 Retrieved from https://hdl.handle.net/10161/33511.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Tendai Kwaramba
Dr. Tendai Kwaramba is a physician-researcher and medical oncologist specializing in gastrointestinal malignancies and global oncology. Her research centers on improving equitable access to cancer prevention, diagnosis, treatment, and survivorship care in resource-limited settings. She leads an ASCO-Conquer Cancer Young Investigator Award–funded study evaluating the implementation of evidence-based treatment de-escalation strategies for early breast cancer in South Africa. Her work bridges health equity, implementation science, and clinical oncology, with a particular focus on optimizing care delivery and resource utilization in low- and middle-income countries.
At Duke Cancer Institute, Dr. Kwaramba is developing research infrastructure that links cancer registry and precision medicine capacity in East Africa. Her broader scholarly portfolio includes work on cancer survivorship risk modeling, early onset cancers, community engagement, disparities in palliative care delivery, and the inclusion of underrepresented populations in cancer research. Drawing on her multidisciplinary background in global health and oncology, Dr. Kwaramba aims to lead collaborative, data-driven initiatives that reduce disparities and advance equitable cancer outcomes worldwide.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.